How do we read bone research — and why is the surrogate-endpoint lesson so sharp here?
Bone research is the sharpest surrogate-versus-outcome classroom in this library: BMD (density) is measurable, fracture (the outcome) is what matters — and the two do not always track. The field's landmark trials (the WHI calcium+D, the bisphosphonate programs, the megadose-bolus nulls and harms) built modern bone medicine, and its frontier — the osteocalcin endocrine story, the mechanostat refinements — keeps redefining what the skeleton is.
The field's surrogate discipline teaches bone-specific reading skills:
Julius Wolff states the principle that bone adapts to the forces placed upon it — the load rule that every exercise prescription, astronaut study, and bed-rest experiment has confirmed since.
The industrial-revolution rickets epidemic meets its cure: sunlight or cod liver oil, either works. The bone-mineralization hormone is found, the fortification era begins.
The remodeling cycle is mapped — osteoclasts, osteoblasts, the Basic Multicellular Unit — and bone turns out to be a continuously renewed tissue, not a static scaffold.
Alendronate and successors prove fracture reduction (the outcome currency) — osteoporosis becomes a treatable chronic disease rather than an aging sentence.
Karsenty's lab reveals bone as an endocrine organ — osteocalcin influencing insulin sensitivity and testosterone. The skeleton joins the metabolic conversation.
Sanders et al.: 500,000 IU once yearly INCREASED falls and fractures in older women — the megadose protocol retired, the daily-rhythm rule established.
Supervised heavy resistance training improves spine density in postmenopausal women with low bone mass — the 'fragile women shouldn't lift' instinct inverted by outcome data.
Romosozumab builds bone; the bone-muscle unit is studied as one system; and the peak-bone-mass childhood story gains the policy attention the age-30 ceiling deserves.
POPULATION · 101 postmenopausal women with low bone mass, supervised heavy lifting vs. low-intensity control, 8 months
FINDING · The heavy-lifting group improved lumbar spine BMD and functional performance; controls declined. No training fractures in the supervised program.
LIMITATION · Small sample, single center, supervision-dependent — the safety profile belongs to supervised progression, not unsupervised improvisation. Our osteoporosis page's exercise anchor.
POPULATION · 36,282 postmenopausal women, 1,000 mg calcium + 400 IU D3 daily vs. placebo, 7 years
FINDING · A modest hip-fracture reduction overall, statistically clearest in adherent women — with a small kidney-stone increase in the supplement arm.
LIMITATION · The 400 IU D dose is below modern targeting; adherence diluted intent-to-treat. The adherent-subgroup signal and the dose limitation are both honest parts of the reading.
POPULATION · 2,256 community-dwelling women aged 70+, single annual 500,000 IU dose, ~3 years
FINDING · The megadose group fell MORE and fractured MORE — approximately 15% higher rates than placebo.
LIMITATION · The single trial that ended a practice; the harm was decisive enough that the protocol was retired worldwide. The rhythm lesson: daily, moderate, sustained.
POPULATION · Large cohorts with protein-intake tracking and bone outcomes
FINDING · Higher protein intake associated with equal or better bone density and lower fracture risk — the acid-ash hypothesis (protein leaches calcium) failing in the modern data.
LIMITATION · Observational; healthy-user patterns persist. But the direction is consistent, the mechanism (IGF-1, the muscle-bone unit) is supportive, and the old fear is retired. Our osteoporosis page's exoneration story.
POPULATION · Postmenopausal women with osteoporosis, alendronate vs. placebo, fracture endpoints
FINDING · Significant reductions in vertebral, hip, and total fractures — the outcome-currency evidence that made bisphosphonates first-line osteoporosis therapy.
LIMITATION · Rare atypical-femur and jaw-necrosis risks at very low absolute rates shaped duration limits and drug holidays; the class remains the benchmark everything on this page is measured against.